Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2001 Jul;74(1):101-8.
doi: 10.1007/BF02982558.

Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura

Affiliations
Case Reports

Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura

S Kinoshita et al. Int J Hematol. 2001 Jul.

Abstract

Upshaw-Schulman syndrome (USS) is a congenital bleeding disorder characterized by repeated episodes of thrombocytopenia and microangiopathic hemolytic anemia that respond to infusions of fresh frozen plasma. Inheritance of USS has been thought to be autosomal recessive, because 2 siblings in the same family are often affected but their parents are asymptomatic. Recently, chronic relapsing thrombotic thrombocytopenic purpura (CR-TTP), reported almost exclusively in adults, was shown to be caused by inherited or acquired deficiency in the activity of a plasma von Willebrand factor-cleaving protease (vWF-CPase). The pathogenesis of USS is unknown, and a relationship between CR-YEP and USS has not been reported. We studied 3 unrelated USS patients (ST, SY, and KI) who presented with severe indirect neonatal hyperbilirubinemia. All 3 patients had undetectable vWF-CPase activity, and the inhibitors to vWF-CPase were all negative. In their parents with no clinical symptoms, vWF-CPase activities as a percentage of control samples (mother/father) were 17/20 for ST, 60/45 for SY, and 36/5.6 for KI. Thus, USS and vWF-CPase activity appear to be coinherited as autosomal recessive traits. Transfusion of fresh frozen plasma in 2 patients (ST and SY) resulted in the expected maximal increment of approximately 7% to 8% in vWF-CPase activity at 1 to 4 hours, but the levels became less than 3% within 2 days. After this decrease, platelet counts increased, plateaued in the normal range at 10 to 12 days, and declined thereafter. Thus, the 2 to 3 weeks of therapeutic benefit from plasma infusions will be discussed in relation to the intravascular lifetime of vWF-CPase.

PubMed Disclaimer

References

    1. N Engl J Med. 1982 Apr 15;306(15):938-9 - PubMed
    1. Blood. 1996 Oct 15;88(8):2939-50 - PubMed
    1. Blood. 1997 Jun 15;89(12):4663-4 - PubMed
    1. Thromb Haemost. 1990 Apr 12;63(2):312-5 - PubMed
    1. Blood. 1997 May 1;89(9):3097-103 - PubMed

Publication types

MeSH terms

LinkOut - more resources